| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:50 UTC |
|---|
| Update Date | 2022-03-07 02:51:44 UTC |
|---|
| HMDB ID | HMDB0014754 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Candoxatril |
|---|
| Description | Candoxatril is only found in individuals that have used or taken this drug. It is the orally-active prodrug of candoxatrilat (UK-73967), the active enantiomer of candoxatrilat (UK-69578), a potent neutral endopeptidase (NEP) inhibitor used in the treatment of chronic heart failure.Neutral endopeptidase inhibitors such as Candoxatril have a dual mechanism of action. They inhibit two metalloprotease enzymes, neutral endopeptidase and ACE, resulting in an increased availability of natriuretic peptides that exhibit vasodilatory effects and, possibly, tissue protective effects. |
|---|
| Structure | COCCOC[C@H](CC1(CCCC1)C(=O)N[C@H]1CC[C@H](CC1)C(O)=O)C(=O)OC1=CC2=C(CCC2)C=C1 InChI=1S/C29H41NO7/c1-35-15-16-36-19-23(27(33)37-25-12-9-20-5-4-6-22(20)17-25)18-29(13-2-3-14-29)28(34)30-24-10-7-21(8-11-24)26(31)32/h9,12,17,21,23-24H,2-8,10-11,13-16,18-19H2,1H3,(H,30,34)(H,31,32)/t21-,23-,24+/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| 4-({1-[(S)-2-(indan-5-yloxycarbonyl)-3-(2-methoxy-ethoxy)-propyl]-cyclopentanecarbonyl}-amino)-cyclohexanecarboxylic acid | ChEBI | | [4(S)-cis]-4-[[[1-[3-[(2,3-Dihydro-1H-indeb5-yl)oxy]-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentyl]carbonyl]amino]cyclohexanecarboxylic acid | ChEBI | | 4-({1-[(S)-2-(indan-5-yloxycarbonyl)-3-(2-methoxy-ethoxy)-propyl]-cyclopentanecarbonyl}-amino)-cyclohexanecarboxylate | Generator | | [4(S)-cis]-4-[[[1-[3-[(2,3-Dihydro-1H-indeb5-yl)oxy]-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentyl]carbonyl]amino]cyclohexanecarboxylate | Generator |
|
|---|
| Chemical Formula | C29H41NO7 |
|---|
| Average Molecular Weight | 515.6383 |
|---|
| Monoisotopic Molecular Weight | 515.288302671 |
|---|
| IUPAC Name | (1s,4s)-4-{1-[(2S)-3-(2,3-dihydro-1H-inden-5-yloxy)-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentaneamido}cyclohexane-1-carboxylic acid |
|---|
| Traditional Name | candoxatril |
|---|
| CAS Registry Number | 118785-03-8 |
|---|
| SMILES | COCCOC[C@H](CC1(CCCC1)C(=O)N[C@H]1CC[C@H](CC1)C(O)=O)C(=O)OC1=CC2=C(CCC2)C=C1 |
|---|
| InChI Identifier | InChI=1S/C29H41NO7/c1-35-15-16-36-19-23(27(33)37-25-12-9-20-5-4-6-22(20)17-25)18-29(13-2-3-14-29)28(34)30-24-10-7-21(8-11-24)26(31)32/h9,12,17,21,23-24H,2-8,10-11,13-16,18-19H2,1H3,(H,30,34)(H,31,32)/t21-,23-,24+/m0/s1 |
|---|
| InChI Key | ZTWZVMIYIIVABD-OEMFJLHTSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as indanes. Indanes are compounds containing an indane moiety, which consists of a cyclopentane fused to a benzene ring. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Benzenoids |
|---|
| Class | Indanes |
|---|
| Sub Class | Not Available |
|---|
| Direct Parent | Indanes |
|---|
| Alternative Parents | |
|---|
| Substituents | - Indane
- Fatty acid ester
- Dicarboxylic acid or derivatives
- Fatty amide
- Fatty acyl
- Carboxamide group
- Secondary carboxylic acid amide
- Carboxylic acid ester
- Ether
- Dialkyl ether
- Carboxylic acid
- Carboxylic acid derivative
- Organooxygen compound
- Organonitrogen compound
- Organic oxygen compound
- Carbonyl group
- Organic nitrogen compound
- Hydrocarbon derivative
- Organic oxide
- Organopnictogen compound
- Aromatic homopolycyclic compound
|
|---|
| Molecular Framework | Aromatic homopolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.0022 g/L | Not Available | | LogP | 3.7 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 7.8 minutes | 32390414 | | Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 6.98 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 18.3396 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.3 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 45.7 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 3345.7 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 260.5 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 248.7 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 183.7 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 392.6 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 734.2 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 746.1 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 117.4 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1730.3 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 710.4 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1923.0 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 469.6 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 479.8 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 248.8 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 195.9 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 10.5 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Candoxatril,1TMS,isomer #1 | COCCOC[C@H](CC1(C(=O)N[C@H]2CC[C@@H](C(=O)O[Si](C)(C)C)CC2)CCCC1)C(=O)OC1=CC=C2CCCC2=C1 | 3935.2 | Semi standard non polar | 33892256 | | Candoxatril,1TMS,isomer #2 | COCCOC[C@H](CC1(C(=O)N([C@H]2CC[C@@H](C(=O)O)CC2)[Si](C)(C)C)CCCC1)C(=O)OC1=CC=C2CCCC2=C1 | 4063.8 | Semi standard non polar | 33892256 | | Candoxatril,2TMS,isomer #1 | COCCOC[C@H](CC1(C(=O)N([C@H]2CC[C@@H](C(=O)O[Si](C)(C)C)CC2)[Si](C)(C)C)CCCC1)C(=O)OC1=CC=C2CCCC2=C1 | 3960.0 | Semi standard non polar | 33892256 | | Candoxatril,2TMS,isomer #1 | COCCOC[C@H](CC1(C(=O)N([C@H]2CC[C@@H](C(=O)O[Si](C)(C)C)CC2)[Si](C)(C)C)CCCC1)C(=O)OC1=CC=C2CCCC2=C1 | 3752.0 | Standard non polar | 33892256 | | Candoxatril,2TMS,isomer #1 | COCCOC[C@H](CC1(C(=O)N([C@H]2CC[C@@H](C(=O)O[Si](C)(C)C)CC2)[Si](C)(C)C)CCCC1)C(=O)OC1=CC=C2CCCC2=C1 | 4730.7 | Standard polar | 33892256 | | Candoxatril,1TBDMS,isomer #1 | COCCOC[C@H](CC1(C(=O)N[C@H]2CC[C@@H](C(=O)O[Si](C)(C)C(C)(C)C)CC2)CCCC1)C(=O)OC1=CC=C2CCCC2=C1 | 4177.0 | Semi standard non polar | 33892256 | | Candoxatril,1TBDMS,isomer #2 | COCCOC[C@H](CC1(C(=O)N([C@H]2CC[C@@H](C(=O)O)CC2)[Si](C)(C)C(C)(C)C)CCCC1)C(=O)OC1=CC=C2CCCC2=C1 | 4288.4 | Semi standard non polar | 33892256 | | Candoxatril,2TBDMS,isomer #1 | COCCOC[C@H](CC1(C(=O)N([C@H]2CC[C@@H](C(=O)O[Si](C)(C)C(C)(C)C)CC2)[Si](C)(C)C(C)(C)C)CCCC1)C(=O)OC1=CC=C2CCCC2=C1 | 4408.7 | Semi standard non polar | 33892256 | | Candoxatril,2TBDMS,isomer #1 | COCCOC[C@H](CC1(C(=O)N([C@H]2CC[C@@H](C(=O)O[Si](C)(C)C(C)(C)C)CC2)[Si](C)(C)C(C)(C)C)CCCC1)C(=O)OC1=CC=C2CCCC2=C1 | 4132.6 | Standard non polar | 33892256 | | Candoxatril,2TBDMS,isomer #1 | COCCOC[C@H](CC1(C(=O)N([C@H]2CC[C@@H](C(=O)O[Si](C)(C)C(C)(C)C)CC2)[Si](C)(C)C(C)(C)C)CCCC1)C(=O)OC1=CC=C2CCCC2=C1 | 4847.2 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Candoxatril GC-MS (Non-derivatized) - 70eV, Positive | splash10-001i-8903400000-268da98bf001b2697ad3 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Candoxatril GC-MS (1 TMS) - 70eV, Positive | splash10-00ea-9701230000-415d420bb3afba46e038 | 2017-10-06 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Candoxatril 90V, Positive-QTOF | splash10-00pl-9200000000-bc11c66d3ece45e09e88 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Candoxatril 75V, Positive-QTOF | splash10-00pi-9600000000-83441da8ede7797f50e7 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Candoxatril 45V, Positive-QTOF | splash10-057r-2900000000-60fd63861087a3fe92d9 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Candoxatril 60V, Positive-QTOF | splash10-057i-6900000000-d1197406ad3d8cefddfa | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Candoxatril 45V, Positive-QTOF | splash10-057r-2900000000-0e86e71ecc29989958e8 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Candoxatril 15V, Positive-QTOF | splash10-053r-0009000000-f592f37f904e3e76bf19 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Candoxatril 30V, Positive-QTOF | splash10-0569-1986000000-e7ba3bddb330c80b7ce9 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Candoxatril 10V, Positive-QTOF | splash10-014i-0714950000-0d88710626c10ccc6895 | 2016-08-02 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Candoxatril 20V, Positive-QTOF | splash10-014i-1924400000-1212988199020b7a6e78 | 2016-08-02 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Candoxatril 40V, Positive-QTOF | splash10-015c-4951100000-c7b3c19e54fc433cebc6 | 2016-08-02 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Candoxatril 10V, Negative-QTOF | splash10-03di-2302690000-82a62f70e9d322ce04e4 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Candoxatril 20V, Negative-QTOF | splash10-0h60-1409510000-c92b3392f22113ddb47a | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Candoxatril 40V, Negative-QTOF | splash10-001i-6910000000-a9c7701cff60595f6454 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Candoxatril 10V, Positive-QTOF | splash10-014i-0001390000-c54e9b5c348fb0757710 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Candoxatril 20V, Positive-QTOF | splash10-017i-3386960000-eb7472fe7ae253206129 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Candoxatril 40V, Positive-QTOF | splash10-0170-6921420000-e5f0c1c9c0d663cf9dff | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Candoxatril 10V, Negative-QTOF | splash10-0bt9-0010910000-64ff1f2df639c0ba09b2 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Candoxatril 20V, Negative-QTOF | splash10-000f-0736910000-09ca3f3a4172911e6edc | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Candoxatril 40V, Negative-QTOF | splash10-01ox-8912370000-d08f092f5a2aef1c655f | 2021-10-11 | Wishart Lab | View Spectrum |
|
|---|